These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 37489050)

  • 1. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK).
    Huang X; You L; Nepovimova E; Psotka M; Malinak D; Valko M; Sivak L; Korabecny J; Heger Z; Adam V; Wu Q; Kuca K
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2237209. PubMed ID: 37489050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials.
    Davoodi-Moghaddam Z; Jafari-Raddani F; Delshad M; Pourbagheri-Sigaroodi A; Bashash D
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15293-15310. PubMed ID: 37594532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
    Shan KS; Bonano-Rios A; Theik NWY; Hussein A; Blaya M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.
    Zhu K; Wu Y; He P; Fan Y; Zhong X; Zheng H; Luo T
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances.
    Khorasani ABS; Hafezi N; Sanaei MJ; Jafari-Raddani F; Pourbagheri-Sigaroodi A; Bashash D
    Cell Biochem Funct; 2024 Apr; 42(3):e3998. PubMed ID: 38561964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
    ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.
    Wani AK; Singh R; Akhtar N; Prakash A; Nepovimova E; Oleksak P; Chrienova Z; Alomar S; Chopra C; Kuca K
    Mini Rev Med Chem; 2024; 24(16):1496-1520. PubMed ID: 38265369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
    Singh P; Kumar V; Gupta SK; Kumari G; Verma M
    Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
    Lim HJ; Crowe P; Yang JL
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidation of the Role of the Epigenetic Regulatory Mechanisms of PI3K/Akt/mTOR Signaling Pathway in Human Malignancies.
    Mohite R; Doshi G
    Curr Cancer Drug Targets; 2024; 24(3):231-244. PubMed ID: 37526459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
    Shorning BY; Dass MS; Smalley MJ; Pearson HB
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.
    Altundag K
    Med Oncol; 2024 Oct; 41(11):279. PubMed ID: 39400749
    [No Abstract]   [Full Text] [Related]  

  • 17. Achieving cancer cell death with PI3K/mTOR-targeted therapies.
    Yea SS; Fruman DA
    Ann N Y Acad Sci; 2013 Mar; 1280(1):15-8. PubMed ID: 23551096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
    Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
    Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.